Project Grant R15HL177621
Award Date
1/15/25
Completion Date
12/31/27
Dollars Obligated
$446K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This federal Project Grant award of $249,000.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Oakland University aims to differentiate the physiological, site-specific production of each tissue factor pathway inhibitor (TFPI) isoform at a molecular level and define their anticoagulant function in embryonic development and disease. The research focuses on understanding the role of TFPI isoforms in maintaining the delicate hemostatic balance...
This Project Grant award of $723,084 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the PAR1/IL-17 signal axis and its role in propagating abnormal chronic thrombus development and pulmonary vascular remodeling in Chronic Thromboembolic Pulmonary Hypertension (CTEPH). The research is being conducted by the University of Colorado-Denver, a prominent public research university, with the goal of advancing...
This Project Grant award of $890,723 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Cleveland State University (CSU) to develop novel mitochondria-targeting peptides (MTPs) as a therapeutic intervention for Barth syndrome, a serious genetic disorder that primarily affects the cardiovascular system. The 3-year project aims to address the critical need for effective treatments targeting the underlying cardiolipin abnormalities...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $434,658 to Oakland University to conduct research on the intracellular function of the platelet protein TREM-like transcript-1 (TLT-1). The research aims to characterize the phosphorylation sites of TLT-1 and decipher the intracellular cues that regulate its trafficking in platelets. The...
This $503,637 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate mechanisms of thrombosis and microclot formation in patients with COVID-19 infection. The study aims to identify novel regulatory mechanisms that lead to hemostatic and fibrinolytic dysfunction, which can contribute to microclot formation and acute/long-term COVID-19 complications. Key objectives include longitudinally tracking...
This Project Grant award, valued at $636,982.00 and awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports research to comprehensively investigate the proteolytic mechanisms that govern the regulation of Factor VIII (FVIII) before and after activation. The goal is to understand how proteolysis of FVIII or FVIII/von Willebrand Factor (VWF) modulates plasma FVIII concentration, as well as the physiological relevance of activated protein...
This $747,281 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will support research to develop a real-time, non-invasive method for characterizing the mechanical properties of blood clots (thrombi) as they age. The goal is to create an ultrasound-based micro-rheology technique that can spatiotemporally quantify evolving thrombus characteristics like age and elasticity in real-time. This is intended to improve understanding...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $760,083 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The grant, titled "The Role of the Protein C System in Trauma Induced Coagulopathy and Thromboinflammation: Mechanisms and Targeted Therapy," aims to advance scientific understanding of the mechanistic underpinnings of trauma-induced coagulopathy...
The federal Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) seeks to validate and extend a platform technology for the delivery of protein-based thrombolytic drugs. The bioengineering strategy employs the designed assembly of endogenous biomolecules, including thrombolytic enzymes and vitamin B12, to create a biocompatible drug delivery platform that leverages the circulatory system as a natural drug depot and...